Kodiak Sciences Inc. (KOD)
NASDAQ: KOD · Real-Time Price · USD
45.89
+3.23 (7.57%)
At close: May 6, 2026, 4:00 PM EDT
45.00
-0.89 (-1.94%)
After-hours: May 6, 2026, 7:58 PM EDT
Kodiak Sciences Employees
Kodiak Sciences had 124 employees as of December 31, 2025. The number of employees increased by 15 or 13.76% compared to the previous year.
Employees
124
Change
15
Growth
13.76%
Revenue / Employee
n/a
Profits / Employee
-$1,854,573
Market Cap
2.85B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 124 | 15 | 13.76% |
| Sep 30, 2025 | 123 | 15 | 13.89% |
| Jun 30, 2025 | 121 | 10 | 9.01% |
| Mar 31, 2025 | 113 | 6 | 5.61% |
| Dec 31, 2024 | 109 | -2 | -1.80% |
| Sep 30, 2024 | 108 | -8 | -6.90% |
| Jun 30, 2024 | 111 | -7 | -5.93% |
| Mar 31, 2024 | 107 | -8 | -6.96% |
| Dec 31, 2023 | 111 | -1 | -0.89% |
| Sep 30, 2023 | 116 | 11 | 10.48% |
| Jun 30, 2023 | 118 | 17 | 16.83% |
| Mar 31, 2023 | 115 | 14 | 13.86% |
| Dec 31, 2022 | 112 | 19 | 20.43% |
| Sep 30, 2022 | 105 | 20 | 23.53% |
| Jun 30, 2022 | 101 | 25 | 32.89% |
| Mar 31, 2022 | 101 | 24 | 31.17% |
| Dec 31, 2021 | 93 | 21 | 29.17% |
| Sep 30, 2021 | 85 | 23 | 37.10% |
| Jun 30, 2021 | 76 | 28 | 58.33% |
| Mar 31, 2021 | 77 | 36 | 87.80% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Denali Therapeutics | 503 |
| Tarsus Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 354 |
| Dyne Therapeutics | 258 |
| Vera Therapeutics | 249 |
| Celldex Therapeutics | 198 |
| Soleno Therapeutics | 182 |
| Immunome | 177 |
KOD News
- 5 days ago - Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences - PRNewsWire
- 19 days ago - Russell 2000 Rips To Record High — Here Are The Top Small Cap Gainers - Benzinga
- 5 weeks ago - Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - PRNewsWire
- 5 weeks ago - Kodiak Sciences: Road To $120 - Forbes
- 5 weeks ago - Kodiak Sciences Stock Is Surging Friday: What's Driving The Action? - Benzinga
- 5 weeks ago - Kodiak Sciences stock soars over 60%: what's behind the sharp rally - Invezz
- 5 weeks ago - Kodiak Sciences shares surge after eye drug succeeds in late-stage study - Reuters
- 5 weeks ago - Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham - PRNewsWire